Pressure BioSciences, Inc. (OTCQB:PBIO)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

Pressure BioSciences Nearing Complete Sellout on Pre-Launch Offering of Game-Changing UST System for Processing CBD Oil into Water-Soluble Nanoemulsions

Company Receives Order for Proprietary BaroShear K45 System from Can B Corp, a Rapidly Growing Health and Wellness Company Dedicated to Delivering Only the Highest Quality CBD Products Nationwide

 

South Easton, MA  – March 12, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer, Can B Corp (OTC: CANBD), for one of its proprietary BaroShear K45 Ultra Shear Technology™ (“UST™”)-based systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the absorption efficiency of today’s macro or microemulsions of CBD Oil.

 

CBD is extracted from the hemp plant in an oil.  As with any oil-based product, it is difficult for the water-based biology of human bodies to access and absorb CBD molecules from relatively large hemp oil droplets. These poor and variable absorption levels of CBD result in low and variable bioavailability of the CBD molecules available in the body for the treatment of targeted conditions. Low or widely varying levels of CBD absorption and bioavailability may significantly impact the effective delivery of the potential benefits of many CBD products on the market today.

 

Mr. Marco Alfonsi, CEO of Can B Corp, said: “It is apparent to us that PBI’s breakthrough UST platform is emerging as a pivotal market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet supplier objectives and consumer demands. Offering effective water solubility of cannabinoids, PBI’s UST-based BaroShear K45 system is expected to produce high CBD absorption rates and bioavailability from ingestion or topical application of cannabinoid products.”

 

Mr. Alfonsi concluded: “We look forward with anticipation to the delivery of the BaroShear K45 system in Q4 2020.  We are excited to be one of only a handful of companies worldwide that will be among the first to have the ability to process cannabinoid products with this revolutionary nanoemulsification system.  We believe the UST-based BaroShear K45 will allow us to reach levels of absorption and bioavailability in our products that far exceed that of other manufacturers on the market today.”

 

Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: “Importantly, the optimized effectiveness for the consumer also translates into allowing top-shelf manufacturers like Can B Corp to achieve targeted product effects from much lower levels of cannabinoids in their marketed products.  This should offer them a dramatic new cost efficiency, for both ingested or topically applied products. We also believe that Can B Corp’s routine use of our BaroShear K45 system will allow them to increase even more the current high-quality level of their products.”

 

Pressure BioSciences’ Board Chairman, Jeffrey N. Peterson, framed a larger perspective: “When I first discovered PBI’s unique high-pressure technologies being applied to extremely challenging life sciences problems many years ago, my chemical engineering education at MIT suddenly stood at attention.  The insights of thermodynamics illuminated a wide range of valuable application possibilities extending far beyond PBI’s initial and successful breakthroughs as a “gentle giant” in sample preparation required by thousands of scientists prior to analytical testing.  A decade later, our innovation of Ultra Shear Technology is allowing valuable materials that exist as oils (and thus do not naturally mix with water) to finally be prepared in effectively water soluble preparations that can be easily absorbed by the water-based biology of our bodies, without requiring heavy use of undesirable chemical additives.”

 

Mr. Peterson continued: “In addition to playing a significant role in the projected $89 billion (by 2024) cannabinoids market (https://mordorintelligence.com/industry-reports/cannabis-market), we expect our patented UST technology platform to transform a vast range of applications that extend across many multi-billion dollar markets, from dairy and other foods/beverages, to pharmaceuticals, nutraceuticals, and industrial applications.  As the UST platform propels PBI into these large and exciting market opportunities, we believe there will be steadily increasing shareholder and market value realization.”

 

About Can B Corp.

Can B Corp (OTC: CANBD) is a Health & Wellness company dedicated to delivering the highest quality CBD products, nutritionals, consumer products, and related medical equipment. Products are sold to consumers online, via retailers, marketing partners, events, and through doctors and other medical and health & wellness organizations. Our products are designed, grown, and produced to the highest industry standards to promote wellness and reduce pain, inflammation, anxiety, sleep disorders and related issues. Further, we are committed to serving our customers and marketing partners, with not only the best products, but the best service and experience in the marketplace now and in the future. Can B Corp owns and operates a manufacturing facility under Pure Health Products in Lacey, Washington where all CBD based products are blended and packaged. Can B Corp owns and operates Duramed Inc, which sells medical supplies and devices. Can B Corp owns and operates NY Hemp Depot and Green Grow Farms, which are licensed to grow and cultivate hemp in the State of New York.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

For more information about PBI and this press release, please click on the following website link:  http://www.pressurebiosciences.com

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory

NEW UST Video Release – Solving Complex Formulation & Processing Challenges By Creating High Quality CBD Oil Nanoemulsions Using Physics not Chemistry

 

South Easton, MA, February 27, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the official opening of its new Ultra Shear Technology™ (“UST™”) Demonstration Laboratory (the “UST Demo Lab”).  The UST Demo Lab is located in the Company’s South Easton, Massachusetts facility.

 

A major purpose of the UST Demo Lab is to showcase the ability of the Company’s revolutionary UST Platform to process CBD oil into true, high quality, water-soluble nanoemulsions. It is expected that nanoemulsions of CBD will be more stable, have superior aesthetic quality, and offer higher bioavailability than the standard macro/microemulsions used in most CBD products today (Nanoemulsions, in Handbook of Nanomaterials in Industrial Applications, Ghodake and Patravale, 2018).  A second purpose is to invite potential purchasers of the Company’s UST-based BaroShear Systems (initial release expected Q4 2020) to evaluate how their CBD and other product formulations work with the Company’s revolutionary UST platform.

 

This Company today released a new short video demonstrating how CBD oil from an independent manufacturer was processed into a clear, water-soluble nanoemulsion using a UST-based, first generation BaroShear system. The video shows the CBD oil and water mixture prior to and after UST processing.

 

Link to new short video showcasing the UST Demonstration Lab: PBI UST CBD Video 022720

 

CBD and other cannabinoids are extracted from the hemp plant in an oil form. The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from ingested or topically applied hemp oil drops.  According to Jason Ellis, President of Vegas CBD Factory, “My colleagues in the cannabis market are beginning to realize that high quality CBD products will only come by using high quality, water-soluble nanoemulsions of CBD oil, such as those generated from processing CBD Oil with PBI’s UST™ platform, which I have observed first-hand in their lab.”

 

Kenneth F. Micciche, Director of PBI’s UST Program, said: “We processed samples of CBD oil formulations from several highly interested companies over the past two months, in an effort to optimize the service we announced today.  The results speak for themselves: one group (Vegas CBD Factory) ordered six BaroShear K45 systems (for Q4 2020 delivery and installation).  We believe several more companies who participated in the early evaluation process are close to giving us their purchase orders.  The ability to showcase the UST platform in real life, and see the final product first-hand, has been shown to be vital to our marketing efforts.  As has been said in the past: ‘build it and they will come’. The opening of the UST Demo Lab is a critical accomplishment in our UST sales and marketing strategy.”

 

Richard T. Schumacher, President and CEO of PBI commented: “The initial reactions from manufacturers of topical and ingestible cannabidiol products processed in our lab during the trial period have been extremely positive. They quickly saw how they could realize substantial cost reductions while eliminating the overloading of poorly water-soluble CBD and other cannabinoids into products to achieve targeted dosing levels. We believe our breakthrough technology platform provides them with a new-found ability to provide safe and effective dosing for their customers, which in turn should stimulate greater growth in the market for CBD-based products overall, and strong sales of our BaroShear product line when it is released to the market later this year.”

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

 

http://www.pressurebiosciences.com

 

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument

Introduction of New Benchtop, R&D Scale, UST-Based “BaroShear Mini” in Q3 2020 Expected to Speed Market Penetration of PBI’s UST Platform for Processing CBD and Other Oils  into Stable, High Quality, Water-Soluble Nanoemulsions

 

New Instrument for Product Formulation and Development to Address Many Large and Diverse Markets 

 

South Easton, MA – January 30, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company plans to release a benchtop, R&D scale, Ultra Shear Technology™ (“UST™”)-based BaroShear instrument to the market in the third quarter of 2020.  The Company believes this new instrument will address a significant un-met need in product formulation and development laboratories in the cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.

 

CBD and other cannabinoids are extracted from the hemp plant in an oil form.  The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from the surface of ingested or topically applied hemp oil droplets. The ultra-low droplet sizes created by UST in nanoemulsions are designed to deliver levels of bioavailability and effectiveness that far exceed the dosing efficiencies achieved from today’s macro or microemulsions of CBD Oil.

 

Kenneth F. Micciche, Director of PBI’s UST Program, said: “We are very excited about the planned release later this year of the third instrument in the BaroShear product family. The aggressive marketing campaign we have underway for the pre-sale of our BaroShear K45 system and for the 2021 release of our industrial-scale BaroShear Max instrument has been well received by manufacturing laboratories. However, it has become apparent that product research and development labs prefer a smaller, bench-top, lower price-point, minimal throughput UST-based instrument. The BaroShear Mini clearly answers that need and will do so without cannibalizing sales to larger manufacturing facilities.  We believe this new instrument will add significantly to PBI’s revenue in 2020.”

 

Richard T. Schumacher, President and CEO of PBI commented: “It has become apparent that Pressure BioSciences’ breakthrough UST platform is a potential market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet consumer and supplier objectives.  By delivering effective water solubility of cannabinoids, PBI’s UST offers the promise of high absorption rates and bioavailability from ingestion or topical application of cannabinoid products. Most importantly, this delivers new confidence in controlled, safe and effective dosing for consumers.  It also offers substantial cost reductions achieved as suppliers can eliminate the overloading of CBD and other cannabinoids into products, previously required to achieve targeted dosing levels.”

 

Jeffrey N. Peterson, PBI Board Chairman, said: “Our innovation of the UST platform offers the potential to allow a universe of valuable materials that exist as oils (and thus do not naturally mix with water) to be delivered in effectively water-soluble preparations that can be easily absorbed by the water-based biology of humans and other animals, or applied in industrial and consumer applications, without requiring heavy use of undesirable chemical additives.”

 

Mr. Peterson continued: “We believe that PBI will transform a vast range of applications with UST, that extend across multiple very large markets from dairy and other foods/beverages, to pharmaceuticals, nutriceuticals, and industrial applications.  This is the technology platform that we believe will propel PBI into multi-billion dollar market opportunities, with resulting market value realization for our shareholders.”

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

 

http://www.pressurebiosciences.com

 

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil

New Order for Six BaroShear K45 Systems Brings Total to Nine Orders Received for Company’s New Ultra Shear Technology™ Based Platform. Additional Orders Expected Shortly  Would Sell Out Planned Initial Build of 12 Systems, with Approximate Total Value of $2.4 Million.

     

South Easton, MA – January 24, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer for six (6) proprietary Ultra Shear Technology™ (“UST™”)-based nanoemulsification systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the bioavailability of today’s macro or microemulsions of CBD Oil.

 

CBD is extracted from the hemp plant in an oil.  As with any oil-based product, it is difficult for the water-based biology of the human body to access and absorb CBD molecules from relatively large hemp oil drops.  This poor and variable absorption of CBD results in low and variable bioavailability of the CBD molecule in the body. Low or widely varying levels of absorption and bioavailability of CBD adversely impacts the effective delivery of the potential benefits of many CBD products on the market today.

 

The purchase order for six BaroShear K45 systems was placed by Mr. Jason Ellis, President of Vegas CBD Factory.  When asked about his order, Mr. Ellis commented: “As consumers rush to try, use and adopt CBD-infused products, it is important to realize that the CBD in the product should be in a high-quality, water-soluble and reliably dosed form.  Proper dosing levels with high bioavailability of CBD from ingested products will in turn increase the chance for the consumer to achieve and optimize the potential beneficial effects of the CBD.”

 

Mr. Ellis continued: “Understanding and addressing this issue is a pivotal challenge for the CBD industry. At Vegas CBD Factory, we have spent a significant amount of time searching for the best method available to make high-quality nanoemulsions of CBD oil.  We have concluded that PBI’s proprietary UST-based platform is the best technology available for achieving optimized dosing and have concluded that to give our customers the best CBD-based product, we should be processing our material using the BaroShear K45 nanoemulsification platform.  Consequently, we have placed an initial order for six K45 systems.”

 

Kenneth F. Micciche, Director of PBI’s UST Program, said: “Recent BaroShear K45 instrument development efforts and demonstrations have propelled a refreshed sales effort for this innovative instrument system since the beginning of 2020. In the first three weeks of this new marketing initiative, we have secured an order for six BaroShear K45 systems and have genuine interest in additional purchases for many more units. We are excited and inspired to see our aggressive new marketing efforts for the BaroShear K45 taking such a strong early hold, and we anticipate further significant orders in the days and weeks ahead.”

 

Richard T. Schumacher, President and CEO of PBI, commented: “In addition to the new order for six BaroShear K45 systems, there are numerous additional groups who have shown high levels of interest in acquiring the new BaroShear K45 nanoemulsification system.  Our team is diligently following up with these interested parties; we believe that several of these groups will be placing purchase orders with us in the very near future. These are very exciting times for all PBI stakeholders.”

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

 

For more information about PBI and this press release, please click on the following website link:  http://www.pressurebiosciences.com

 

Investor Contacts:

Richard T. Schumacher, President and CEO

(508) 230-1828

Kenneth F. Micciche, Director – UST Program    

(508) 230-1829

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine

Cannabis Brightline Article Highlights Potential of PBI’s UST Platform to Play Significant Role in Multiple Billion Dollar Markets – Including CBD, Cosmetics, Nutraceuticals, Biopharmaceuticals, and Food/Beverage

 

South Easton, MA – January 17, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company’s new and innovative Ultra Shear Technology™ (“UST™”) platform was featured in Cannabis Brightline, one of North America’s leading cannabis publications. The article was written and published by Focus Media Group (FMG) of Halifax, NS, Canada.

 

Jason Ellis, President of Vegas CBD Factory, is a recognized expert in the manufacture of cannabinoid-based products. Vegas CBD Factory is located in a 70,000 sq. ft. cGMP and FDA-compliant, state-of-the-art facility in Las Vegas, NV. Mr. Ellis said: “This article highlights a critical issue facing the cannabis market today: the low bioavailability of CBD from CBD-infused products. Because oils (including CBD oil) are not well-absorbed by the water-based systems of humans and other animals, most CBD delivered by ingestion is unfortunately flushed from the body, with very little being absorbed to provide its expected beneficial effects.”

 

Mr. Ellis continued: “The article by Cannabis Brightline is very timely, as my colleagues in the cannabis market are now beginning to realize that top quality CBD products will only be generated from using high quality, water-soluble nanoemulsions of CBD oil. I have observed first-hand how existing so-called nanoemulsions of CBD oil flatly fail to deliver effective water-solubility or absorption. Conversely, nanoemulsions created by processing CBD oil through PBI’s UST platform provided astonishingly immediate and visually apparent water solubility, which years of science tells us will lead to greatly increased bioavailability. We are now considering the purchase of multiple PBI BaroShear K45 UST nanoemulsion systems in 2020.”

 

The Cannabis Brightline article also discussed two other patented and broadly enabling technology platforms developed, owned, and marketed by PBI. In addition, it included a short summary of the important work being supported by PBI’s novel pressure-based instruments in such areas as cancer, heart disease, stroke, infectious diseases, and Alzheimer’s Disease. The article is available online and can be accessed by clicking on the following link: The Solution for Maximizing the Bioavailability of CBD and Beyond.

 

Richard T. Schumacher, President and CEO of PBI, commented: “It has been very exciting to experience the rapidly growing increase in interest in our UST-based BaroShear K45 nanoemulsification system since the first of the year. In just the past week, we have received nearly a dozen unsolicited phone calls/emails from individuals in North America and Europe. Many callers were aware that our initial build of 12 BaroShear K45 instruments is expected to begin in early 2020, and they wanted to ensure they could secure a spot on the initial build purchase list.”

 

Mr. Schumacher continued: “Because of strong and growing interest, we remain comfortable with our earlier guidance that BaroShear K45 revenue in 2020 will greatly exceed current revenue from our PCT and BaroFold platforms combined. We look forward with anticipation to the initial release of the BaroShear K45 nanoemulsification system, currently planned for September 2020.”

 

About Cannabis Brightline

With thousands of subscribers, Cannabis Brightline is one of North America’s leading publications in the cannabis industry. Cannabis has quickly grown into a major economic sector in North America. It is the mission of Cannabis Brightline to help facilitate that growth by giving readers a look into what makes industry leaders successful. We do so by connecting supporting businesses, new technologies, and amazing communities to reveal a thriving industry. Cannabis Brightline (www.cannabisbrightline.com) is written and published by Focus Media Group (Halifax, NS, Canada).

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

Investor Contacts:

Richard T. Schumacher, President and CEO, (508) 230-1828 (T)
Kenneth F. Micciche, Director – UST Program, (508) 230-1829 (F)

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

 

Source:  Pressure BioSciences, Inc.

About Pressure BioSciences


Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology (“PCT”), (ii)  BaroFold Platform, and (iii) Ultra Shear Technology (“UST”).

 

To date, we have installed over 300 PCT systems in approximately 200 sites worldwide. There are over 120 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

 

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently-released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs.  The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in over 200 academic, government, pharmaceutical, and biotech research laboratories worldwide.  There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company’s Research Products & Services Group.

 

The BaroFold Platform can be used to significantly impact and improve the quality of protein therapeutics.  It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies.  The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The BaroFold Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scaleable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations.  Research and manufacturing licenses are available.

 

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

 

MANAGEMENT

 

Richard T. SchumacherRichard T. Schumacher

President, Chief Executive Officer and Director

Mr. Richard T. Schumacher, the founder of our Company, has served as a director of Pressure BioSciences since the formation of its legacy business, Boston Biomedica, Inc., in 1978. He has served as CEO of Pressure BioSciences since April 2004 and President since September, 2004. He previously served as CEO and Chairman of the Board of Boston Biomedica from 1992 to February, 2003 and as President from 1986 to August 1999. Mr. Schumacher served as the Director of Infectious Disease Services for Clinical Sciences Laboratory, a New England-based medical reference laboratory, from 1986 to 1988. From 1972 to 1985, Mr. Schumacher was employed by the Center for Blood Research, a nonprofit medical research institute associated with Harvard Medical School. Mr. Schumacher received a BS in Zoology from the University of New Hampshire.

 

 

Edmund Ting, Ph.D.Edmund Ting, Ph.D.

Senior Vice President of Engineering

Dr. Edmund Ting joined Pressure BioSciences as Senior Vice President of Engineering in April, 2006. Prior to joining the company, Dr. Ting served as the Chief Research Officer of Avure Technologies, a leading worldwide manufacturer of high pressure hydrostatic processing equipment for the food and materials processing industry, Flow International Corporation, a world leader in the ultrahigh pressure waterjet cutting technology market, and the parent company of Avure Technologies. Dr. Ting last held the position of VP of Engineering Research and Development at Flow International Corporation. Dr. Ting was also a research scientist and a group leader at Grumman Aerospace Corporation. Dr. Ting earned a BS degree in mechanical engineering from Northeastern University and a Sc.D. in materials science and engineering from the Massachusetts Institute of Technology.

 

 

Alexander Lazarev, Ph.D.Alexander Lazarev, Ph.D.

Chief Science Officer

Dr. Alexander Lazarev, Ph.D. joined Pressure BioSciences in April, 2006 as Director of Research and Development and was promoted to Vice President of Research and Development in March, 2007. Dr. Lazarev was promoted to Chief Science Officer in December, 2018. Prior to joining Pressure BioSciences, Dr. Lazarev worked as a Visiting Scientist at the Barnett Institute of Chemical and Biological Analysis at Northeastern University, and served as a Director of New Technology Development at Proteome Systems, Inc., where he was involved in research and development of innovative proteomic analysis applications. Dr. Lazarev previously held senior research positions at Genomic Solutions, Inc. and PhytoChem Technologies, Inc. Most of Dr. Lazarev’s scientific career has been dedicated to development of methods and applications for biochemical analysis. Dr. Lazarev has been elected as an Executive Board member of the MASSEP.org, a non-profit scientific discussion forum dedicated to the promotion and improvement of chromatography and other analytical technologies. Dr. Lazarev earned his undergraduate and graduate degrees at the University of Kazan, Russian Federation.

 

Source:  https://www.pressurebiosciences.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Pressure BioSciences, Inc. current news coverage by the company.  FNMG HOLDS NO SHARES OF Pressure BioSciences, Inc.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!